The PHA Preceptorship Program is designed to improve competence, performance and patient care practices by instructing front-line clinicians in the highest quality of care for patients with PAH by combining didactic discourse and highly interactive case-based discussion. At the conclusion of this program, participants should be able to:
- Define key pathophysiologic and epidemiologic components of PAH
- Accurately diagnose patients through comprehensive screening and early recognition of symptoms
- Evaluate the patient’s condition and prescribe optimal long-term management, including knowing when and how to treat and when to consult with colleagues at an established PAH center
- Tailor comprehensive care for complex patient populations
Washington University School of Medicine designates this live activity for a maximum of 5.0 AMA PRA Category 1 Credits™.
|Actelion Pharmaceuticals US, Inc.
||Gilead Sciences, Inc.
United Therapeutics Corporation
This is a program of the PHA Medical Education Fund, made possible through unrestricted educational grants from our supporters.